[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616117":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":28,"collaborators":11,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":11,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":39,"enrollmentInfo":40,"targetDuration":11,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":11,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":11},{"fullName":5,"class":6},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental group","EXPERIMENTAL",null,[13],"Drug: liraglutide combined with orlistat",{"label":15,"type":16,"description":11,"interventionNames":17},"control group","ACTIVE_COMPARATOR",[18],"Drug: liraglutide monotherapy",[20,24],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","liraglutide monotherapy",[15],{"type":21,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"liraglutide combined with orlistat","combination therapy",[9],{"type":29,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100616117","phase-4-rws-of-of-liraglutide-alone-and-in-combination-with-orlistat-for-weight-loss-in-overweightobese-patients-100616117",false,"NCT07301437","RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight\u002FObese Patients.","A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight\u002FObese Patients.","Inclusion Criteria:\n\n* BMI: ≤ 35 kg\u002Fm² and ≥ 30 kg\u002Fm², or ≥ 27 kg\u002Fm² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)\n* Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.\n* No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.\n\nExclusion Criteria:\n\n* Allergy to liraglutide, orlistat or excipients\n* Severe liver and kidney dysfunction: ALT or AST\\> three times the upper limit of normal, or eGFR \\\u003C30 mL\u002Fmin\n* Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism\u002Fhypothyroidism\n* Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers\n* Pregnant or lactating women\n* Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).","ALL","18 Years","65 Years",{"count":41,"type":42},120,"ESTIMATED","INTERVENTIONAL",[45],"PHASE4","To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight\u002Fobese patients.",[48],"Overweight and Obese Adults","NOT_YET_RECRUITING","2026-03-20",{"date":52,"type":53},"2026-03-23","ACTUAL",{"date":55,"type":42},"2026-05-01",{"date":57,"type":42},"2027-08-31",{"name":5,"class":6}]